Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Laboratory Medicine, Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen, China.
Clin Biochem. 2023 Jun;116:59-64. doi: 10.1016/j.clinbiochem.2023.03.011. Epub 2023 Mar 20.
To retrospectively compare the clinical effects of the newly released 2021 and 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations for estimated glomerular filtration rate based on creatinine (eGFRcr) in a Chinese population with a broad spectrum of clinical characteristics using historical data.
Patients and healthy individuals who visited the Zhongshan Hospital, Fudan University, between July 1, 2020, and July 1, 2022, were enrolled. The exclusion criteria were age < 18 years, amputees, pregnant women, patients with muscle-related diseases, and patients who had undergone ultrafiltration or dialysis. The final study population included 1,051,827 patients with a median age of 57 years; 57.24% of the enrolled individuals were men. eGFRcr was calculated using the 2009 and 2021 CKD-EPI equations and initial creatinine level. Results were evaluated statistically by sex, age, creatinine level, and CKD stage.
The 2021 equation increased the eGFRcr in all participants compared to the 2009 equation by 4.46%. The median eGFRcr deviation of the 2021 CKD-EPI equation compared to the 2009 CKD-EPI equation was 4 ml/min/1.73 m. 903,443 subjects (85.89%) had higher eGFRcr owing to the utilization of the 2021 CKD-EPI equation, which did not cause CKD stage change. A total of 11.57% of subjects (121,666) had improved CKD stage with the 2021 CKD-EPI equation. 1.79% (18,817) had the same CKD stage with both equations, and 0.75% (7,901) had lower eGFRcr but no change in the CKD stage with the 2021 equation.
The 2021 CKD-EPI equation typically produces higher eGFRcr results than the 2009 version. Applying the new equation could lead to changes in the CKD stage for some patients, which doctors should consider.
利用历史数据,回顾性比较 2021 年和 2009 年慢性肾脏病流行病学合作(CKD-EPI)公式在具有广泛临床特征的中国人群中基于肌酐的估计肾小球滤过率(eGFRcr)的临床效果。
2020 年 7 月 1 日至 2022 年 7 月 1 日,复旦大学中山医院就诊的患者和健康个体被纳入研究。排除标准为年龄<18 岁、截肢者、孕妇、肌肉相关疾病患者和接受超滤或透析的患者。最终研究人群包括 1051827 例中位年龄为 57 岁的患者;纳入个体中 57.24%为男性。使用 2009 年和 2021 年 CKD-EPI 方程和初始肌酐水平计算 eGFRcr。按性别、年龄、肌酐水平和 CKD 分期进行统计学评估结果。
与 2009 年方程相比,2021 年方程在所有参与者中均使 eGFRcr 升高了 4.46%。2021 年 CKD-EPI 方程与 2009 年 CKD-EPI 方程相比,eGFRcr 的中位数偏差为 4ml/min/1.73m。由于使用了 2021 年 CKD-EPI 方程,85.89%(903443 例)的受试者的 eGFRcr 更高,这并没有导致 CKD 分期的变化。共有 11.57%(121666 例)的受试者的 CKD 分期因 2021 年 CKD-EPI 方程而得到改善。两种方程均为 1.79%(18817 例)的受试者的 CKD 分期相同,而 0.75%(7901 例)的受试者的 eGFRcr 较低,但 CKD 分期在使用 2021 年方程时没有变化。
2021 年 CKD-EPI 方程通常产生比 2009 年版本更高的 eGFRcr 结果。对于一些患者,应用新方程可能会导致 CKD 分期的变化,医生应考虑这一点。